The impact of a bloodless medicine program on pancreatic resections: A single-institution experience incorporating patients with borderline-resectable and locally advanced pancreatic cancer

Gabriel D. Ivey , Julia Purchla , Nicolas C. Cruz , Ananda Thomas , Thomas J. McPhaul , Christopher R. Shubert , Kelly J. Lafaro , Richard A. Burkhart , John L. Cameron , Jin He , Steven M. Frank , William R. Burns
{"title":"The impact of a bloodless medicine program on pancreatic resections: A single-institution experience incorporating patients with borderline-resectable and locally advanced pancreatic cancer","authors":"Gabriel D. Ivey ,&nbsp;Julia Purchla ,&nbsp;Nicolas C. Cruz ,&nbsp;Ananda Thomas ,&nbsp;Thomas J. McPhaul ,&nbsp;Christopher R. Shubert ,&nbsp;Kelly J. Lafaro ,&nbsp;Richard A. Burkhart ,&nbsp;John L. Cameron ,&nbsp;Jin He ,&nbsp;Steven M. Frank ,&nbsp;William R. Burns","doi":"10.1016/j.soi.2024.100065","DOIUrl":null,"url":null,"abstract":"<div><h3>Background</h3><p>Patients undergoing pancreatic resection who decline blood transfusion represent a clinical challenge. While bloodless medicine programs are valuable, their impact remains unclear, especially for those with borderline-resectable and locally advanced pancreatic ductal adenocarcinoma (PDAC).</p></div><div><h3>Methods</h3><p>Retrospective review of institutional databases identified patients who did not accept blood transfusion and underwent pancreatic resection from 2013–2022. We collated hemoglobin values, interventions to minimize symptomatic anemia, and patient outcomes.</p></div><div><h3>Results</h3><p>Thirteen patients were identified. Median age was 63 years (range: 52–75 years) and eight (61.5 %) were female. All procedures were performed electively for invasive malignancy with PDAC as the most common diagnosis (11/13; 84.6 %) and pancreaticoduodenectomy as the most common procedure (11/13; 84.6 %). Vascular involvement was common in the 11 patients with PDAC (borderline-resectable: 7/11; 63.6 % and locally advanced: 3/11; 27.3 %), as was the use of multi-agent chemotherapy (n = 10) and preoperative radiotherapy (n = 8) prior to surgery. Median blood loss was 400 mL (range: 100–2200 mL). Intraoperative measures included acute normovolemic hemodilution in one patient and red blood cell salvage in three patients. Median preoperative hemoglobin was 12.3 g/dL (range: 10.3–14.2 g/dL) and median nadir hemoglobin was 9.2 g/dL (range: 5.2–11.8 g/dL). Median hospital stay was 10 days (range: 6–42 days). Thirty-day mortality was 0 % and one-year overall survival was 69.2 % with median follow-up of 26.4 months.</p></div><div><h3>Conclusion</h3><p>Pancreatic resections can be performed safely in patients who decline blood transfusion, even with borderline-resectable and locally advanced PDAC. Avoiding transfusions and employing blood-conservation techniques does not appear to detrimentally impact survival.</p></div>","PeriodicalId":101191,"journal":{"name":"Surgical Oncology Insight","volume":null,"pages":null},"PeriodicalIF":0.0000,"publicationDate":"2024-06-05","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S2950247024000744/pdfft?md5=1f16ecb3f86784aa69ded03ef5fdc121&pid=1-s2.0-S2950247024000744-main.pdf","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Surgical Oncology Insight","FirstCategoryId":"1085","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S2950247024000744","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 0

Abstract

Background

Patients undergoing pancreatic resection who decline blood transfusion represent a clinical challenge. While bloodless medicine programs are valuable, their impact remains unclear, especially for those with borderline-resectable and locally advanced pancreatic ductal adenocarcinoma (PDAC).

Methods

Retrospective review of institutional databases identified patients who did not accept blood transfusion and underwent pancreatic resection from 2013–2022. We collated hemoglobin values, interventions to minimize symptomatic anemia, and patient outcomes.

Results

Thirteen patients were identified. Median age was 63 years (range: 52–75 years) and eight (61.5 %) were female. All procedures were performed electively for invasive malignancy with PDAC as the most common diagnosis (11/13; 84.6 %) and pancreaticoduodenectomy as the most common procedure (11/13; 84.6 %). Vascular involvement was common in the 11 patients with PDAC (borderline-resectable: 7/11; 63.6 % and locally advanced: 3/11; 27.3 %), as was the use of multi-agent chemotherapy (n = 10) and preoperative radiotherapy (n = 8) prior to surgery. Median blood loss was 400 mL (range: 100–2200 mL). Intraoperative measures included acute normovolemic hemodilution in one patient and red blood cell salvage in three patients. Median preoperative hemoglobin was 12.3 g/dL (range: 10.3–14.2 g/dL) and median nadir hemoglobin was 9.2 g/dL (range: 5.2–11.8 g/dL). Median hospital stay was 10 days (range: 6–42 days). Thirty-day mortality was 0 % and one-year overall survival was 69.2 % with median follow-up of 26.4 months.

Conclusion

Pancreatic resections can be performed safely in patients who decline blood transfusion, even with borderline-resectable and locally advanced PDAC. Avoiding transfusions and employing blood-conservation techniques does not appear to detrimentally impact survival.

查看原文
分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
无血医学项目对胰腺切除术的影响:纳入边缘可切除和局部晚期胰腺癌患者的单一机构经验
背景接受胰腺切除术的患者拒绝输血是一项临床挑战。虽然无血医学项目很有价值,但其影响仍不明确,尤其是对那些边缘可切除和局部晚期胰腺导管腺癌(PDAC)患者。方法回顾性审查机构数据库,确定了 2013-2022 年间不接受输血并接受胰腺切除术的患者。我们整理了血红蛋白值、为尽量减少症状性贫血而采取的干预措施以及患者的预后。中位年龄为 63 岁(范围:52-75 岁),其中 8 人(61.5%)为女性。所有手术均为侵袭性恶性肿瘤的择期手术,PDAC 是最常见的诊断(11/13;84.6%),胰十二指肠切除术是最常见的手术(11/13;84.6%)。在 11 名 PDAC 患者中,血管受累很常见(边缘可切除:7/11;63.6%;局部晚期:3/11;27.3%),术前使用多药化疗(10 人)和术前放疗(8 人)也很常见。失血量中位数为400毫升(范围:100-2200毫升)。术中措施包括对一名患者进行急性常容量血液稀释,对三名患者进行红细胞抢救。术前血红蛋白中位数为 12.3 g/dL(范围:10.3-14.2 g/dL),最低血红蛋白中位数为 9.2 g/dL(范围:5.2-11.8 g/dL)。住院时间中位数为 10 天(范围:6-42 天)。30天死亡率为0%,一年总生存率为69.2%,中位随访时间为26.4个月。结论即使是边缘可切除和局部晚期PDAC患者,如果拒绝输血,也可以安全地进行胰腺切除术。避免输血和采用血液保存技术似乎不会对生存造成不利影响。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 去求助
来源期刊
自引率
0.00%
发文量
0
期刊最新文献
Combining liver-directed and immunotherapy in advanced hepatocellular carcinoma: A review and future directions Timing of breast biopsy and axillary ultrasound does not affect the false positive rate of the axillary ultrasound Small bowel cancers: A population-based analysis of epidemiology, treatment and outcomes in Ontario, Canada from 2005-2020 Pelvic Floor Physical Therapy Prehabilitation (PrePFPT) for the prevention of low anterior resection syndrome Pepsinogen and Helicobacter pylori: Serum biomarkers for gastric cancer risk in a diverse United States population
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1